First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
Recruiting · NCT05104515 · Registry updated 2025-02-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2025-02-14 | NCT05104515 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Oxford Vacmedix UK Ltd. | 1 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Oxford University Hospitals NHS Foundation Trust | Oxford | United Kingdom | 24 |
| Sarah Cannon Research Institute UK | London | United Kingdom | 4 |
| The Christie NHS Foundation Trust | Manchester | United Kingdom | 113 |
| University College London Hospitals NHS Foundation Trust | London | United Kingdom | 1 |